Literature DB >> 21854537

Concentrate-related inhibitor risk: is a difference always real?

A Iorio, M Marcucci, M Makris.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21854537     DOI： 10.1111/j.1538-7836.2011.04480.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

Review 1.  Present and future challanges in the treatment of haemophilia: a clinician's perspective.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 2.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

Review 3.  Switching treatments in haemophilia: is there a risk of inhibitor development?

Authors:  Elena Santagostino; Günter Auerswald; Gary Benson; Gerry Dolan; Victor Jiménez-Yuste; Thierry Lambert; Rolf Ljung; Massimo Morfini; Eduardo Remor; Silva Zupančić Šalek
Journal:  Eur J Haematol       Date:  2014-09-17       Impact factor: 2.997

Review 4.  Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Authors:  Flora Peyvandi; Syna Miri; Isabella Garagiola
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.